Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure

Abstract Background There is currently insufficient information available on effective therapies that can be administered to patients with non‐small cell cancer (NSCLC) who develop resistance to epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs). However, sequential treatment vi...

Full description

Bibliographic Details
Main Authors: Kyoichi Kaira, Kunihiko Kobayashi, Ayako Shiono, Ou Yamaguchi, Kosuke Hashimoto, Atsuto Mouri, Shun Shinomiya, Yu Miura, Hisao Imai, Hiroshi Kagamu
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Thoracic Cancer
Subjects:
EGFR‐TKI
immune checkpoint inhibitor
lung cancer
PD‐1
rechallenge
Online Access:https://doi.org/10.1111/1759-7714.13864

Internet

https://doi.org/10.1111/1759-7714.13864

Similar Items